ASHBURN, Va., Feb. 19, 2013 /PRNewswire/ -- Innocoll, Inc. announced the launch of its new CollaCare website, www.collacareproducts.com. The new, standalone website is designed to be the primary source of information on the full range of products in the CollaCare family for patients, practitioners and marketing partners. All key information on the product family has been incorporated onto the website in a readily accessible and user friendly manner.
Innocoll's CollaCare portfolio of products consists of sterile, biodegradable, advanced wound management devices, wound dressings, topical anesthetics, dental and skin care products that cover a broad range of indications.
Commenting on the announcements, Dr. Michael Myers, Innocoll's President and CEO said, "We are very pleased to announce the launch of this new website. Given the broad range of products within the CollaCare family, we believe that a standalone website is merited." Dr. Myers further commented, "We have seen how valuable a resource our CollaGUARD adhesion barrier website has become and look forward to a similar outcome for CollaCare."
The CollaCare products were developed using Innocoll's proprietary collagen based technologies. The products are versatile, easy to handle, fully resorbable and cover a broad range of indications and therapeutic areas.
The CollaCare portfolio of wound management products include regenerative dressings to treat chronic and acute wounds; pressure ulcers, venous stasis ulcers, diabetic ulcers and burns; topical powders that absorb wound exudate, and dental sponges for use during oral and maxillofacial surgeries.
- CollaCare Sponge
- CollaCare Powder
- CollaCare Dental
About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil™, CollaPress™ and Liquicoll®.
Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.
Products in clinical and regulatory development include: Cogenzia® in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, XaraColl® in phase 3 development for the management of post-operative pain and Durieva™, a dura on-lay/ dura replacement product. For more information, please visit www.innocollinc.com.
SOURCE Innocoll, Inc.